Joseph Stringer
Stock Analyst at Needham
(4.87)
# 319
Out of 4,969 analysts
632
Total ratings
47.6%
Success rate
24.7%
Average return
Main Sectors:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIOA BioAge Labs | Reiterated: Buy | $35 | $8.48 | +312.74% | 8 | Sep 14, 2026 | |
| IFRX InflaRx | Initiated Coverage: Buy | $8 | $2.12 | +277.36% | 1 | Sep 14, 2026 | |
| IONS Ionis Pharmaceuticals | Reiterated: Buy | $86 | $51.44 | +67.19% | 46 | Sep 8, 2026 | |
| MRNA Moderna | Reiterated: Hold | n/a | $146.69 | - | 44 | Aug 19, 2026 | |
| ANNX Annexon | Reiterated: Buy | $25 | $3.95 | +532.91% | 39 | Aug 12, 2026 | |
| PLRX Pliant Therapeutics | Reiterated: Hold | n/a | $1.15 | - | 34 | Aug 12, 2026 | |
| STTK Shattuck Labs | Reiterated: Buy | $17 | $6.20 | +174.19% | 6 | Aug 11, 2026 | |
| PCVX Vaxcyte | Reiterated: Buy | $110 | $59.54 | +84.75% | 42 | Aug 6, 2026 | |
| VIR Vir Biotechnology | Reiterated: Buy | $18 | $10.77 | +67.21% | 47 | Aug 6, 2026 | |
| GILD Gilead Sciences | Reiterated: Buy | $170 | $146.41 | +16.11% | 31 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $130 | $102.44 | +26.90% | 48 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $29.60 | +35.14% | 46 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $519.51 | - | 33 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $510 → $357 | $249.99 | +42.81% | 48 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 → $22 | $8.68 | +153.46% | 75 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.98 | n/a | 28 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.83 | n/a | 33 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $17.03 | n/a | 13 | Dec 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $26 | $27.52 | n/a | 5 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $157.22 | n/a | 3 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $170 | $52.96 | n/a | 2 | Apr 28, 2021 |
BioAge Labs
Sep 14, 2026
Reiterated: Buy
Price Target: $35
Current: $8.48
Upside: +312.74%
InflaRx
Sep 14, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $2.12
Upside: +277.36%
Ionis Pharmaceuticals
Sep 8, 2026
Reiterated: Buy
Price Target: $86
Current: $51.44
Upside: +67.19%
Moderna
Aug 19, 2026
Reiterated: Hold
Price Target: n/a
Current: $146.69
Upside: -
Annexon
Aug 12, 2026
Reiterated: Buy
Price Target: $25
Current: $3.95
Upside: +532.91%
Pliant Therapeutics
Aug 12, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.15
Upside: -
Shattuck Labs
Aug 11, 2026
Reiterated: Buy
Price Target: $17
Current: $6.20
Upside: +174.19%
Vaxcyte
Aug 6, 2026
Reiterated: Buy
Price Target: $110
Current: $59.54
Upside: +84.75%
Vir Biotechnology
Aug 6, 2026
Reiterated: Buy
Price Target: $18
Current: $10.77
Upside: +67.21%
Gilead Sciences
Aug 5, 2026
Reiterated: Buy
Price Target: $170
Current: $146.41
Upside: +16.11%
Aug 4, 2026
Reiterated: Buy
Price Target: $130
Current: $102.44
Upside: +26.90%
Aug 4, 2026
Reiterated: Buy
Price Target: $40
Current: $29.60
Upside: +35.14%
Aug 4, 2026
Reiterated: Hold
Price Target: n/a
Current: $519.51
Upside: -
Jul 30, 2026
Reiterated: Buy
Price Target: $510 → $357
Current: $249.99
Upside: +42.81%
Jul 30, 2026
Reiterated: Buy
Price Target: $28 → $22
Current: $8.68
Upside: +153.46%
Apr 21, 2025
Rated: Hold
Price Target: n/a
Current: $1.98
Upside: n/a
Aug 16, 2024
Rated: Hold
Price Target: n/a
Current: $1.83
Upside: n/a
Dec 23, 2022
Rated: Hold
Price Target: n/a
Current: $17.03
Upside: n/a
Aug 5, 2021
Rated: Buy
Price Target: $30 → $26
Current: $27.52
Upside: n/a
Aug 4, 2021
Rated: Hold
Price Target: n/a
Current: $157.22
Upside: n/a
Apr 28, 2021
Rated: Buy
Price Target: $170
Current: $52.96
Upside: n/a